André C. Kalil

27.0k citations

169 papers · 9.1k indexed · 5 hit papers · h-index 44

Impact in

Critical Care and Intensive Care Medicine top 0.05%
- Nosocomial Infections in ICU
Applied Microbiology and Biotechnology top 0.1%
- Antibiotic Use and Resistance

Papers in

Critical Care and Intensive Care Medicine 46
- Nosocomial Infections in ICU 33
- Intensive Care Unit Cognitive Disorders 13
Applied Microbiology and Biotechnology 9

Co-authors: Diana F. Florescu Paul D. Fey Michael Klompas Daniel A. Sweeney Naomi P. O’Grady John G. Bartlett Paul G. Thomas Mark L. Metersky
Journals: Critical Care Medicine (19 papers)Clinical Infectious Diseases (18 papers)Intensive Care Medicine (8 papers)Clinical Microbiology and Infection (6 papers)Clinical Transplantation (6 papers)
Partner nations: United States Brazil France

In The Last Decade

André C. Kalil

160 papers receiving 8.8k citations

Hit Papers

5 papers align trajectories log scale

How to use biomarkers of infection or sepsis at the bedside: guide to clinicians 2023 · 134 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2023 Intensive Care Medicine
2020 JAMA
2019 Critical Care
2016 Clinical Infectious Diseases
2016 Clinical Infectious Diseases

Peers

Countries citing papers authored by André C. Kalil

Since Specialization

Citations

This map shows the geographic impact of André C. Kalil's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by André C. Kalil with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites André C. Kalil more than expected).

Fields of papers citing papers by André C. Kalil

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by André C. Kalil. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by André C. Kalil. The network helps show where André C. Kalil may publish in the future.

Co-authorship network

The 25 scholars most cited alongside André C. Kalil, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with André C. Kalil Line = papers co-authored together André C. Kalil links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	How to approach a patient hospitalized for pneumonia who is not responding to treatment? Intensive Care Medicine ·Pedro Póvoa, Luís Coelho, Jordi Carratalà, Kelly Cawcutt, Sara E. Cosgrove, Ricard Ferrer, Carlos A. Gómez, Michael Klompas, Thiago Lisboa, Ignacio Martín‐Loeches, Saad Nseir, Jorge I. Salluh, Sias Scherger, Daniel A. Sweeney, André C. Kalil	2025	4
2	Remdesivir-Associated Survival Outcomes Among Immunocompromised Patients Hospitalized for COVID-19: Real-world Evidence From the Omicron-Dominant Era Clinical Infectious Diseases ·Essy Mozaffari, Aastha Chandak, Robert Gottlieb, Rizqi Ragil Ayuningtyas, Mark Berry, Alpesh Amin, Paul E. Sax, André C. Kalil	2024	3
3	Remdesivir is Associated with Reduced Mortality in Patients Hospitalized for COVID-19 Not Requiring Supplemental Oxygen Open Forum Infectious Diseases ·Essy Mozaffari, Aastha Chandak, Rizqi Ragil Ayuningtyas, André C. Kalil, Heng Jiang, Eunyoung Lee, Плотников Илья Викторович, Mark Thrun, Mark Berry, Richard Haubrich, Robert Gottlieb	2024	6
4	Remdesivir Effectiveness in Reducing the Risk of 30-Day Readmission in Vulnerable Patients Hospitalized for COVID-19: A Retrospective US Cohort Study Using Propensity Scores Clinical Infectious Diseases ·Essy Mozaffari, Aastha Chandak, Robert Gottlieb, André C. Kalil, E.Yu. Pustova, N Phelps, Mark Berry, Rizqi Ragil Ayuningtyas, Alpesh Amin	2024	1
5	Treatment of patients hospitalized for COVID-19 with remdesivir is associated with lower likelihood of 30-day readmission: a retrospective observational study Journal of Comparative Effectiveness Research ·Essy Mozaffari, Aastha Chandak, Robert Gottlieb, Rizqi Ragil Ayuningtyas, André C. Kalil, Vishnudas Sarda, Плотников Илья Викторович, N Phelps, Mark Berry, Alpesh Amin	2024	2
6	Public Health Benefits of Applying Evidence-Based Best Practices in Managing Patients Hospitalized for COVID-19 Clinical Infectious Diseases ·André C. Kalil, Aastha Chandak, Luke Moore, Neera Ahuja, Martin Kolditz, Roman Casciano, Ananth Kadambi, Mohsen Yaghoubi, Sotirios Tsiodras, Jakob J Malin, Essy Mozaffari, Michele Bartoletti	2024	0
7	Biomarkers in pulmonary infections: a clinical approach Annals of Intensive Care ·Pedro Póvoa, Luís Coelho, Jauharul Akfiya Sudjaelan, Adrián Ceccato, Andrew Conway Morris, Jorge I. Salluh, Vandack Nobre, Saad Nseir, Ignacio Martín‐Loeches, Thiago Lisboa, Paula Ramírez, Anahita Rouzé, Daniel A. Sweeney, André C. Kalil	2024	15
8	Which trial do we need? One or two antimicrobials with anti-pseudomonal activity for the empirical treatment of ventilator-associated pneumonia due to Gram-negative bacteria Clinical Microbiology and Infection ·Erlangga Yusuf, Alexandre Prehn Zavascki, Henrik Endeman, André C. Kalil	2023	0
9	Improving Sepsis Outcomes in the Era of Pay-for-Performance and Electronic Quality Measures: A Joint IDSA/ACEP/PIDS/SHEA/SHM/SIDP Position Paper Clinical Infectious Diseases ·Chanu Rhee, Jeffrey R. Strich, Kathleen Chiotos, David C. Classen, Sara E. Cosgrove, G. Glioti, Emily L. Heil, Sameer S. Kadri, André C. Kalil, David N. Gilbert, Henry Masur, Edward Septimus, Daniel A. Sweeney, N Vaingankar, Dean L. Winslow, Donald M. Yealy, Michael Klompas	2023	20
10	Remdesivir Is Associated With Reduced Mortality in COVID-19 Patients Requiring Supplemental Oxygen Including Invasive Mechanical Ventilation Across SARS-CoV-2 Variants Open Forum Infectious Diseases ·Essy Mozaffari, Aastha Chandak, Robert Gottlieb, Rizqi Ragil Ayuningtyas, Stephanie H. Read, Eunyoung Lee, Плотников Илья Викторович, Ю. Ю. Герасименко, Mark Berry, Camilo Uribe, André C. Kalil	2023	19
11	How to use biomarkers of infection or sepsis at the bedside: guide to clinicians Intensive Care Medicine ·Pedro Póvoa, Luís Coelho, Felipe Dal‐Pizzol, Ricard Ferrer, Angela Huttner, Andrew Conway Morris, Vandack Nobre, Paula Ramírez, Anahita Rouzé, Jorge I. Salluh, Mervyn Singer, Daniel A. Sweeney, Antoní Torres, Grant Waterer, André C. Kalil Hit paper breakdown →	2023	134
12	Which trial do we need? Doxycycline in combination with ceftriaxone for the treatment of community-acquired pneumonia Clinical Microbiology and Infection ·Ryan C. Maves, André C. Kalil	2023	2
13	Remdesivir Reduced Mortality in Immunocompromised Patients Hospitalized for COVID-19 Across Variant Waves: Findings From Routine Clinical Practice Clinical Infectious Diseases ·Essy Mozaffari, Aastha Chandak, Robert Gottlieb, Rizqi Ragil Ayuningtyas, Stephanie H. Read, Heng Jiang, 董耀祖, Eunyoung Lee, Ю. Ю. Герасименко, Mark Berry, André C. Kalil	2023	34
14	American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID‐19 Pandemic: Version 2 Arthritis & Rheumatology ·Ted R. Mikuls, Sindhu R. Johnson, Liana Fraenkel, Reuben J. Arasaratnam, Lindsey R. Baden, Bonnie L. Bermas, Winn Chatham, Stanley Cohen, Karen H. Costenbader, Ellen M. Gravallese, André C. Kalil, Michael E. Weinblatt, Kevin Winthrop, Amy S. Mudano, Amy S. Turner, Kenneth G. Saag	2020	42
15	American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID‐19 Pandemic: Version 1 Arthritis & Rheumatology ·Ted R. Mikuls, Sindhu R. Johnson, Liana Fraenkel, Reuben J. Arasaratnam, Lindsey R. Baden, Bonnie L. Bermas, (unknown), Stanley Cohen, Karen H. Costenbader, Ellen M. Gravallese, André C. Kalil, Michael E. Weinblatt, Kevin Winthrop, Amy S. Mudano, Amy S. Turner, Kenneth G. Saag	2020	97
16	American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID‐19 Pandemic: Version 3 Arthritis & Rheumatology ·Ted R. Mikuls, Sindhu R. Johnson, Liana Fraenkel, Reuben J. Arasaratnam, Lindsey R. Baden, Bonnie L. Bermas, Winn Chatham, Stanley Cohen, Karen H. Costenbader, Ellen M. Gravallese, André C. Kalil, Michael E. Weinblatt, Kevin Winthrop, Amy S. Mudano, Amy S. Turner, Kenneth G. Saag	2020	145
17	Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society Clinical Infectious Diseases ·André C. Kalil, Mark L. Metersky, Michael Klompas, John Muscedere, Daniel A. Sweeney, Lucy B. Palmer, Lena M. Napolitano, Naomi P. O’Grady, John G. Bartlett, Jordi Carratalà, Ali A. El Solh, Santiago Ewig, Paul D. Fey, Thomas M. File, Marcos I. Restrepo, Jason A. Roberts, Grant Waterer, Peggy Cruse, Shandra L. Knight, Jan Brożek Hit paper breakdown →	2016	2347
18	Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: A systematic review and meta-analysis* Critical Care Medicine ·André C. Kalil, Kai Yee Toh, Elizabeth D. Hermsen, Felipe Kalil Neto, Junfeng Sun, Mark E. Rupp	2010	83
19	Linezolid versus Vancomycin or Teicoplanin for Nosocomial Pneumonia: A Meta-Analysis 46th Annual Meeting ·André C. Kalil	2008	4
20	Risk and the Efficacy of Antiinflammatory Agents: Retrospective and Confirmatory Studies of Sepsis American Journal of Respiratory and Critical Care Medicine ·Peter Q. Eichacker, Chantal Parent, André C. Kalil, Congcong Wang, Xizhong Cui, Steven M. Banks, Eric Gerstenberger, Yvonne Fitz, Robert L. Danner, Charles Natanson	2002	250

About André C. Kalil

André C. Kalil is a scholar working on Critical Care and Intensive Care Medicine, Applied Microbiology and Biotechnology, Infectious Diseases, Epidemiology and Transplantation, having authored 169 papers that have together received 9.1k indexed citations. Recurring topics across this work include Nosocomial Infections in ICU (33 papers), Sepsis Diagnosis and Treatment (29 papers), Pneumonia and Respiratory Infections (27 papers), Cytomegalovirus and herpesvirus research (26 papers), COVID-19 Clinical Research Studies (21 papers), Intensive Care Unit Cognitive Disorders (13 papers), Long-Term Effects of COVID-19 (12 papers) and Herpesvirus Infections and Treatments (11 papers). The work is most often cited by research in Critical Care and Intensive Care Medicine (2.6k citations), Applied Microbiology and Biotechnology (868 citations), Molecular Medicine (1.1k citations), Epidemiology (5.0k citations) and Infectious Diseases (2.3k citations). André C. Kalil has collaborated with scholars based in United States, Brazil and France. Frequent co-authors include Diana F. Florescu, Paul D. Fey, Michael Klompas, Daniel A. Sweeney, Naomi P. O’Grady, John G. Bartlett, Paul G. Thomas, Mark L. Metersky, Alison G. Freifeld and Grant Waterer. Their work appears in journals such as Critical Care Medicine, Clinical Infectious Diseases, Intensive Care Medicine, Clinical Microbiology and Infection and Clinical Transplantation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact